The future of antidepressants.
A common action of many antidepressants is the inhibition of the reuptake of the biogenic amines norepinephrine, serotonin (5-HT) and/or dopamine into nerve terminals. Another postulated mechanism of action for many antidepressants is the downregulation of beta-adrenergic receptors postsynaptically after chronic administration. Many antidepressants have been reported to produce changes in the regulation of 5-HT1 and 5-HT2 receptors chronically. None of these mechanisms is completely satisfactory as a common antidepressant mechanism of action. Is it possible to unify these hypotheses of antidepressant action? A number of receptor changes have been recognized in depression. Usually, these implicated receptors are linked to a G protein. Thus, it could be hypothesized that depression may be the result of a disorder of the large family of receptor-linked G proteins. Depression, a disorder in which there seems to be an important genetic component, could be expressed in either the receptor or in the G proteins, leading to a defective linkage between the receptor and the G protein, resulting in abnormal transduction mechanisms. The concept of antidepressants is changing rapidly as these agents appear with new therapeutic indications other than depression, such as panic disorder, obsessive compulsive disorder, etc. It can be expected that the presently available antidepressants might eventually be considered anxiolytics or that benzodiazepines and 5-HT1A agonists could come to be viewed as disinhibiting substances.
Bourin
M
M
GIS Médicament, Faculté de Médecine, Nantes, France.
Baker
G B
GB
D000928:Antidepressive Agents / Q000145:classification* / Q000378:metabolism / Q000494:pharmacology; D003866:Depressive Disorder / Q000188:drug therapy*; D005544:Forecasting; D019204:GTP-Binding Proteins / Q000378:metabolism; D006801:Humans; D011955:Receptors, Drug / Q000378:metabolism
D000928:Antidepressive Agents; D011955:Receptors, Drug; D019204:GTP-Binding Proteins